サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1708012

肺がんリキッドバイオプシーの世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Lung Cancer Liquid Biopsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 180 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺がんリキッドバイオプシーの世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月14日
発行: Persistence Market Research
ページ情報: 英文 180 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な調査結果

  • 肺がんリキッドバイオプシーの市場規模：8億2,470万米ドル（2025年）
  • 予測される市場金額：19億50万米ドル（2032年）
  • 世界市場の成長率：12.7%（2025年～2032年のCAGR）

肺がんリキッドバイオプシー市場 - レポート範囲

肺がんリキッドバイオプシー市場は、肺がん患者の腫瘍バイオマーカーを検出するために血液やその他の体液を利用する非侵襲的診断法に焦点を当てています。これらの生検は、迅速な納期、患者の不快感の軽減、腫瘍の進行や治療効果のリアルタイムモニタリングにより、がんの診断と管理に革命をもたらしています。肺がん罹患率が世界的に上昇し、精密医療の採用が進む中、リキッドバイオプシーは腫瘍診断における強力なツールとして台頭しつつあります。この市場には、小細胞肺がん（SCLC）と非小細胞肺がん（NSCLC）の両方における早期発見、遺伝子プロファイリング、治療方針の決定のために設計された器具、試薬、バイオインフォマティクスソリューションを含む幅広い製品とサービスが含まれます。

市場成長の促進要因

世界の肺がんリキッドバイオプシー市場の成長は、世界的な肺がんの有病率の上昇と、低侵襲診断法に対する需要の高まりによって大きく促進されています。分子診断、特に次世代シーケンシング（NGS）とPCRベースの技術における技術の進歩は、リキッドバイオプシー検査をより正確で利用しやすいものにしています。加えて、個別化医療への注目の高まりは、医療提供者や腫瘍医がリアルタイムの腫瘍プロファイリングやモニタリングにリキッドバイオプシーを採用することを後押ししています。規制当局の支持的な承認と、特に先進国で顕著な医療費の増加が、市場の拡大にさらに寄与しています。早期の正確ながん検出法への選好の高まりと、従来の組織生検の限界を克服するリキッドバイオプシーの可能性も、市場の需要を後押ししています。

市場抑制要因

有望な成長軌道にもかかわらず、肺がんリキッドバイオプシー市場は複数の主要な課題に直面しています。先進のリキッドバイオプシー技術に伴う高いコストが、特に中低所得国での採用を制限する可能性があります。一部のアッセイの感度と特異度は、特に早期がん検出において、偽陽性または偽陰性を引き起こす可能性があり、依然として懸念事項です。地域によっては、患者や医療提供者の認知度が低いことも、市場浸透の妨げとなっています。さらに、厳しい規制枠組みや償還のハードルは、製品の上市を遅らせたりアクセスを制限したりして、市場全体の成長に影響を及ぼす可能性があります。

市場機会

肺がんリキッドバイオプシー市場は、診断精度を高めることができる細胞外小胞や循環腫瘍細胞などの新たなバイオマーカー研究の拡大により、大きな機会をもたらしています。進行中の多分析リキッドバイオプシーパネルの開発とバイオインフォマティクスにおけるAIと機械学習の統合は、診断精度と効率性の向上への道筋を提供します。特にアジア太平洋やラテンアメリカなどの新興経済国は、がん罹患率の増加や医療インフラの拡大により、未開発の可能性を秘めています。さらに、標的治療におけるコンパニオン診断に向けた診断企業と製薬企業との提携は、新たな成長の道を開いています。新たなバイオマーカーの組み合わせの検証を目的とした研究開発と臨床試験への継続的な投資は、技術革新と市場での競争力を促進すると考えられます。

当レポートでは、世界の肺がんリキッドバイオプシー市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 製品採用分析
  • 疾病の疫学
  • 規制情勢
  • サプライヤーリスト
  • ポーターのファイブフォース分析
  • PESTLE分析
  • プロモーション戦略：主要企業別

第4章 世界の肺がんリキッドバイオプシーの見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界の肺がんリキッドバイオプシーの見通し：製品
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：製品別（2019年～2024年）
    • 現在の市場規模の分析と予測：製品別（2025年～2032年）
      • 器具
      • キット、試薬
      • ソフトウェア、サービス
    • 市場の魅力分析：製品
  • 世界の肺がんリキッドバイオプシーの見通し：技術
    • イントロダクション/主な調査結果
    • 市場規模の実績：技術別（2019年～2024年）
    • 現在の市場規模の分析と予測：技術別（2025年～2032年）
      • マルチ遺伝子並列解析（NGS）
      • 単一遺伝子解析（PCRマイクロアレイ）
    • 市場の魅力分析：技術
  • 世界の肺がんリキッドバイオプシーの見通し：バイオマーカー
    • イントロダクション/主な調査結果
    • 市場規模の実績：バイオマーカー別（2019年～2024年）
    • 現在の市場規模の分析と予測：バイオマーカー別（2025年～2032年）
      • cfDNA
      • ctDNA
      • 細胞外小胞（EV）
      • 循環腫瘍細胞（CTC）
      • その他
    • 市場の魅力分析：バイオマーカー
  • 世界の肺がんリキッドバイオプシーの見通し：適応症
    • イントロダクション/主な調査結果
    • 市場規模の実績：適応症別（2019年～2024年）
    • 現在の市場規模の分析と予測：適応症別（2025年～2032年）
      • 小細胞肺がん（SCLC）
      • 非小細胞肺がん（NSCLC）
    • 市場の魅力分析：適応症
  • 世界の肺がんリキッドバイオプシーの見通し：サンプル
    • イントロダクション/主な調査結果
    • 市場規模の実績、サンプル別（2019年～2024年）
    • 現在の市場規模の分析と予測：サンプル別（2025年～2032年）
      • 血液
      • 脳脊髄液（CSF）
      • 血漿
      • 血清
      • その他
    • 市場の魅力分析：サンプル
  • 世界の肺がんリキッドバイオプシーの見通し：エンドユーザー
    • イントロダクション/主な調査結果
    • 市場規模の実績：エンドユーザー別（2019年～2024年）
    • 現在の市場規模の分析と予測：エンドユーザー別（2025年～2032年）
      • 病院
      • リファレンスラボ
      • 学術研究機関
      • その他
    • 市場の魅力分析：エンドユーザー

第5章 世界の肺がんリキッドバイオプシーの見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の肺がんリキッドバイオプシーの見通し

第7章 欧州の肺がんリキッドバイオプシーの見通し

第8章 東アジアの肺がんリキッドバイオプシーの見通し

第9章 南アジア・オセアニアの肺がんリキッドバイオプシーの見通し

第10章 ラテンアメリカの肺がんリキッドバイオプシーの見通し

第11章 中東・アフリカの肺がんリキッドバイオプシーの見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Oncocyte Corporation
    • NeoGenomics Laboratories
    • Lepu Medical Technology (Beijing) Co., Ltd
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Sysmex Corporation
    • BioView
    • Guardant Health, Inc
    • SOPHiA GENETICS
    • BioMark Diagnostics
    • DELFI Diagnostics, Inc.
    • Freenome Holdings, Inc.
    • Foresight Diagnostics, Inc.
    • Foundation Medicine, Inc.
    • Pillar Biosciences, Inc.
    • Caris Life Sciences

第13章 付録

目次
Product Code: PMRREP35195

Persistence Market Research has recently released a comprehensive report on the global Lung Cancer Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Lung Cancer Liquid Biopsy Market Size (2025E): US$ 824.7 Mn
  • Projected Market Value (2032F): US$ 1,900.5 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 12.7%

Lung Cancer Liquid Biopsy Market - Report Scope:

The lung cancer liquid biopsy market focuses on non-invasive diagnostic methods that utilize blood and other body fluids to detect tumor biomarkers in lung cancer patients. These biopsies are revolutionizing cancer diagnostics and management by offering quicker turnaround times, reduced patient discomfort, and real-time monitoring of tumor progression or therapy response. With rising lung cancer incidence globally and increasing adoption of precision medicine, liquid biopsy is emerging as a powerful tool in oncology diagnostics. This market includes a wide range of products and services, including instruments, reagents, and bioinformatics solutions designed for early detection, genetic profiling, and therapeutic decision-making in both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC).

Market Growth Drivers:

The growth of the global lung cancer liquid biopsy market is being significantly driven by the rising global prevalence of lung cancer, coupled with a growing demand for minimally invasive diagnostic procedures. Technological advancements in molecular diagnostics, particularly in next-generation sequencing (NGS) and PCR-based techniques, are making liquid biopsy tests more accurate and accessible. Additionally, increasing focus on personalized medicine is pushing healthcare providers and oncologists to adopt liquid biopsies for real-time tumor profiling and monitoring. Supportive regulatory approvals and increasing healthcare spending, especially in developed nations, are further contributing to market expansion. The growing preference for early and precise cancer detection methods and the potential of liquid biopsies to overcome limitations of traditional tissue biopsies are also propelling market demand.

Market Restraints:

Despite the promising growth trajectory, the lung cancer liquid biopsy market faces several key challenges. High costs associated with advanced liquid biopsy technologies can restrict adoption, particularly in low- and middle-income countries. The sensitivity and specificity of some assays, especially in early-stage cancer detection, remain areas of concern, potentially leading to false positives or negatives. Limited awareness among patients and healthcare providers in certain regions further impedes market penetration. Additionally, stringent regulatory frameworks and reimbursement hurdles can delay product launches and limit accessibility, affecting overall market growth.

Market Opportunities:

The lung cancer liquid biopsy market presents considerable opportunities fueled by the expansion of research into new biomarkers, including extracellular vesicles and circulating tumor cells, which can enhance diagnostic accuracy. The ongoing development of multi-analyte liquid biopsy panels and integration of AI and machine learning in bioinformatics offer pathways to improved diagnostic precision and efficiency. Emerging economies, especially across Asia-Pacific and Latin America, represent untapped potential with growing cancer burden and expanding healthcare infrastructure. Furthermore, collaborations between diagnostic companies and pharmaceutical firms for companion diagnostics in targeted therapies are opening new growth avenues. Continued investment in R&D and clinical trials aimed at validating new biomarker combinations will likely drive innovation and market competitiveness.

Key Questions Answered in the Report:

  • What are the primary factors driving the global lung cancer liquid biopsy market's growth?
  • Which regions and market segments are experiencing the highest demand for lung cancer liquid biopsy diagnostics?
  • How are advancements in genomics and personalized oncology influencing market dynamics?
  • Who are the key players in the lung cancer liquid biopsy market, and what strategies are they adopting to stay competitive?
  • What are the emerging trends and future projections for the global lung cancer liquid biopsy market?

Competitive Intelligence and Business Strategy:

Leading players in the global lung cancer liquid biopsy market, such as Bio-Rad Laboratories, Agilent Technologies, Thermo Fisher Scientific, Illumina, and F. Hoffmann-La Roche, are focusing on developing high-sensitivity diagnostic platforms and expanding their liquid biopsy portfolios. These companies are increasingly investing in strategic collaborations with research institutions and biotech firms to enhance their R&D capabilities. Mergers, acquisitions, and licensing agreements are common strategies aimed at boosting technological integration and expanding global reach. Key players are also emphasizing regulatory approvals and global certifications to gain market trust and improve reimbursement prospects. Efforts to combine multiple biomarkers into single-panel tests and the integration of cloud-based platforms for data interpretation are setting new standards in the field.

Companies Covered in This Report:

  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Oncocyte Corporation
  • NeoGenomics Laboratories
  • Lepu Medical Technology (Beijing) Co., Ltd
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Sysmex Corporation
  • BioView

Market Segmentation

By Product:

  • Instruments
  • Kits and Reagents
  • Software and Services

By Technology:

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR, Microarrays)

By Biomarker:

  • Cell-free DNA (cfDNA)
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vesicles (EVs)
  • Circulating Tumor Cells (CTC)
  • Others

By Indication:

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)

By Sample:

  • Blood
  • Cerebrospinal Fluid (CSF)
  • Plasma
  • Serum
  • Others

By End-user:

  • Hospitals
  • Reference Laboratories
  • Academic & Research Centers
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Lung Cancer Liquid Biopsy Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Disease Epidemiology
  • 3.3. Regulatory Landscape
  • 3.4. List of Suppliers
  • 3.5. Porter's Five Forces Analysis
  • 3.6. PESTLE Analysis
  • 3.7. Promotional Strategies, By Key Players

4. Global Lung Cancer Liquid Biopsy Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Lung Cancer Liquid Biopsy Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Kits and Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Lung Cancer Liquid Biopsy Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Multi-gene-parallel Analysis (NGS)
      • 4.4.3.2. Single Gene Analysis (PCR Microarrays)
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn), By Biomarker, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
      • 4.5.3.1. Cell-free DNA (cfDNA)
      • 4.5.3.2. Circulating tumor DNA (ctDNA)
      • 4.5.3.3. Extracellular Vesicles (EVs)
      • 4.5.3.4. Circulating Tumor Cells (CTC)
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: Biomarker
  • 4.6. Global Lung Cancer Liquid Biopsy Outlook: Indication
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
    • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.6.3.1. Small Cell Lung Cancer (SCLC)
      • 4.6.3.2. Non-Small Cell Lung Cancer (NSCLC)
    • 4.6.4. Market Attractiveness Analysis: Indication
  • 4.7. Global Lung Cancer Liquid Biopsy Outlook: Sample
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Mn), By Sample, 2019-2024
    • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
      • 4.7.3.1. Blood
      • 4.7.3.2. Cerebrospinal Fluid (CSF)
      • 4.7.3.3. Plasma
      • 4.7.3.4. Serum
      • 4.7.3.5. Others
    • 4.7.4. Market Attractiveness Analysis: Sample
  • 4.8. Global Lung Cancer Liquid Biopsy Outlook: End User
    • 4.8.1. Introduction / Key Findings
    • 4.8.2. Historical Market Size (US$ Mn), By End User, 2019-2024
    • 4.8.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.8.3.1. Hospitals
      • 4.8.3.2. Reference Laboratories
      • 4.8.3.3. Academic & Research Institutes
      • 4.8.3.4. Others
    • 4.8.4. Market Attractiveness Analysis: End User

5. Global Lung Cancer Liquid Biopsy Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Lung Cancer Liquid Biopsy Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Technology
    • 6.2.4. By Biomarker
    • 6.2.5. By Indication
    • 6.2.6. By Sample
    • 6.2.7. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Kits and Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Multi-gene-parallel Analysis (NGS)
    • 6.5.2. Single Gene Analysis (PCR Microarrays)
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 6.6.1. Cell-free DNA (cfDNA)
    • 6.6.2. Circulating tumor DNA (ctDNA)
    • 6.6.3. Extracellular Vesicles (EVs)
    • 6.6.4. Circulating Tumor Cells (CTC)
    • 6.6.5. Others
  • 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.7.1. Small Cell Lung Cancer (SCLC)
    • 6.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 6.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 6.8.1. Blood
    • 6.8.2. Cerebrospinal Fluid (CSF)
    • 6.8.3. Plasma
    • 6.8.4. Serum
    • 6.8.5. Others
  • 6.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.9.1. Hospitals
    • 6.9.2. Reference Laboratories
    • 6.9.3. Academic & Research Institutes
    • 6.9.4. Others
  • 6.10. Market Attractiveness Analysis

7. Europe Lung Cancer Liquid Biopsy Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Technology
    • 7.2.4. By Biomarker
    • 7.2.5. By Indication
    • 7.2.6. By Sample
    • 7.2.7. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Kits and Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Multi-gene-parallel Analysis (NGS)
    • 7.5.2. Single Gene Analysis (PCR Microarrays)
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 7.6.1. Cell-free DNA (cfDNA)
    • 7.6.2. Circulating tumor DNA (ctDNA)
    • 7.6.3. Extracellular Vesicles (EVs)
    • 7.6.4. Circulating Tumor Cells (CTC)
    • 7.6.5. Others
  • 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.7.1. Small Cell Lung Cancer (SCLC)
    • 7.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 7.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 7.8.1. Blood
    • 7.8.2. Cerebrospinal Fluid (CSF)
    • 7.8.3. Plasma
    • 7.8.4. Serum
    • 7.8.5. Others
  • 7.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.9.1. Hospitals
    • 7.9.2. Reference Laboratories
    • 7.9.3. Academic & Research Institutes
    • 7.9.4. Others
  • 7.10. Market Attractiveness Analysis

8. East Asia Lung Cancer Liquid Biopsy Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Technology
    • 8.2.4. By Biomarker
    • 8.2.5. By Indication
    • 8.2.6. By Sample
    • 8.2.7. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Kits and Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Multi-gene-parallel Analysis (NGS)
    • 8.5.2. Single Gene Analysis (PCR Microarrays)
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 8.6.1. Cell-free DNA (cfDNA)
    • 8.6.2. Circulating tumor DNA (ctDNA)
    • 8.6.3. Extracellular Vesicles (EVs)
    • 8.6.4. Circulating Tumor Cells (CTC)
    • 8.6.5. Others
  • 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.7.1. Small Cell Lung Cancer (SCLC)
    • 8.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 8.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 8.8.1. Blood
    • 8.8.2. Cerebrospinal Fluid (CSF)
    • 8.8.3. Plasma
    • 8.8.4. Serum
    • 8.8.5. Others
  • 8.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.9.1. Hospitals
    • 8.9.2. Reference Laboratories
    • 8.9.3. Academic & Research Institutes
    • 8.9.4. Others
  • 8.10. Market Attractiveness Analysis

9. South Asia & Oceania Lung Cancer Liquid Biopsy Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Technology
    • 9.2.4. By Biomarker
    • 9.2.5. By Indication
    • 9.2.6. By Sample
    • 9.2.7. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Kits and Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Multi-gene-parallel Analysis (NGS)
    • 9.5.2. Single Gene Analysis (PCR Microarrays)
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 9.6.1. Cell-free DNA (cfDNA)
    • 9.6.2. Circulating tumor DNA (ctDNA)
    • 9.6.3. Extracellular Vesicles (EVs)
    • 9.6.4. Circulating Tumor Cells (CTC)
    • 9.6.5. Others
  • 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.7.1. Small Cell Lung Cancer (SCLC)
    • 9.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 9.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 9.8.1. Blood
    • 9.8.2. Cerebrospinal Fluid (CSF)
    • 9.8.3. Plasma
    • 9.8.4. Serum
    • 9.8.5. Others
  • 9.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.9.1. Hospitals
    • 9.9.2. Reference Laboratories
    • 9.9.3. Academic & Research Institutes
    • 9.9.4. Others
  • 9.10. Market Attractiveness Analysis

10. Latin America Lung Cancer Liquid Biopsy Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Technology
    • 10.2.4. By Biomarker
    • 10.2.5. By Indication
    • 10.2.6. By Sample
    • 10.2.7. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Kits and Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Multi-gene-parallel Analysis (NGS)
    • 10.5.2. Single Gene Analysis (PCR Microarrays)
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 10.6.1. Cell-free DNA (cfDNA)
    • 10.6.2. Circulating tumor DNA (ctDNA)
    • 10.6.3. Extracellular Vesicles (EVs)
    • 10.6.4. Circulating Tumor Cells (CTC)
    • 10.6.5. Others
  • 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.7.1. Small Cell Lung Cancer (SCLC)
    • 10.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 10.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 10.8.1. Blood
    • 10.8.2. Cerebrospinal Fluid (CSF)
    • 10.8.3. Plasma
    • 10.8.4. Serum
    • 10.8.5. Others
  • 10.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.9.1. Hospitals
    • 10.9.2. Reference Laboratories
    • 10.9.3. Academic & Research Institutes
    • 10.9.4. Others
  • 10.10. Market Attractiveness Analysis

11. Middle East & Africa Lung Cancer Liquid Biopsy Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Technology
    • 11.2.4. By Biomarker
    • 11.2.5. By Indication
    • 11.2.6. By Sample
    • 11.2.7. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Kits and Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Multi-gene-parallel Analysis (NGS)
    • 11.5.2. Single Gene Analysis (PCR Microarrays)
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 11.6.1. Cell-free DNA (cfDNA)
    • 11.6.2. Circulating tumor DNA (ctDNA)
    • 11.6.3. Extracellular Vesicles (EVs)
    • 11.6.4. Circulating Tumor Cells (CTC)
    • 11.6.5. Others
  • 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.7.1. Small Cell Lung Cancer (SCLC)
    • 11.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 11.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 11.8.1. Blood
    • 11.8.2. Cerebrospinal Fluid (CSF)
    • 11.8.3. Plasma
    • 11.8.4. Serum
    • 11.8.5. Others
  • 11.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.9.1. Hospitals
    • 11.9.2. Reference Laboratories
    • 11.9.3. Academic & Research Institutes
    • 11.9.4. Others
  • 11.10. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Bio-Rad Laboratories, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Agilent Technologies, Inc.
    • 12.3.3. Oncocyte Corporation
    • 12.3.4. NeoGenomics Laboratories
    • 12.3.5. Lepu Medical Technology(Beijing)Co.,Ltd
    • 12.3.6. QIAGEN
    • 12.3.7. Thermo Fisher Scientific Inc.
    • 12.3.8. Illumina, Inc.
    • 12.3.9. F. Hoffmann-La Roche Ltd
    • 12.3.10. Sysmex Corporation
    • 12.3.11. BioView
    • 12.3.12. Guardant Health, Inc
    • 12.3.13. SOPHiA GENETICS
    • 12.3.14. BioMark Diagnostics
    • 12.3.15. DELFI Diagnostics, Inc.
    • 12.3.16. Freenome Holdings, Inc.
    • 12.3.17. Foresight Diagnostics, Inc.
    • 12.3.18. Foundation Medicine, Inc.
    • 12.3.19. Pillar Biosciences, Inc.
    • 12.3.20. Caris Life Sciences

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations